Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Colorectal Cancer MetastaticBrain Metastases, AdultRas (KRAS or NRAS) Gene MutationBRAF Gene MutationHER2 Gene MutationMSI
Interventions
DIAGNOSTIC_TEST

Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI

"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."

Trial Locations (1)

115478

RECRUITING

Blokhin's Russian Cancer Research Center, Moscow

All Listed Sponsors
lead

Blokhin's Russian Cancer Research Center

OTHER